together with the quebec consortium for drug discovery (cqdm), brain canada is pleased to share an upcoming funding opportunity for canadian researchers. cqdm’s quantum leap pharma-led funding program for drug discovery research aims to support innovative translational biopharmaceutical research projects that are at advanced stages of development and that have the potential to improve, facilitate and/or accelerate the drug discovery process and the development of safer and more effective drugs.

projects selected as part of the quantum leap program focus on developing cutting-edge technologies with the potential to significantly advance the r&d activities of cqdm’s pharmaceutical members. quantum leap projects are executed in close collaboration and with the expert support and funds of pharmaceutical members.

brain canada is partnering with the quantum leap pharma-led funding program for drug discovery research on eligible brain related projects.

please note: budget structures can vary depending on each project, please contact cqdm to confirm eligibility before applying.

for more details, please email cqdm at appliquez-apply@cqdm.org and visit their website here. 

funding for the quantum leap partnership has been made possible thanks to brain canada and the cqdm.

call for proposals are open year-round for quantum leap projects.

deadline to participate in the next selection round is may 19, 2022.

the fy22 defense appropriations act is anticipated to provide funding for the pcrp to support innovative, high-impact prostate cancer research.  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 pcrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

the mission of the fy22 pcrp is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of service members, veterans, and all the men and their families who are experiencing the impact of the disease.  within this context, the pcrp is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following fy22 pcrp overarching challenges:

• ·        improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer

applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness.  studies should consider both short- and long-term quality of life outcomes.  areas of particular interest include:

o   the mental and emotional health of patients and their families/caregivers

o   impact of quality of life considerations on decision-making after diagnosis and/or treatment

o   identification of vulnerable groups of men and their families at great risk of quality of life detriments

o   translation of factors or interventions that improve quality of life outcomes and overall health and wellness

• ·        develop treatments that improve outcomes for men with lethal prostate cancer

applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence.  refer to the national comprehensive cancer network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

• ·        advance health equity and reduce disparities in prostate cancer

applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer. 

inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors.

health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients. 

high-risk populations include, but are not limited to, people of african descent (including caribbean), genetically predisposed populations, service members, and veterans.

underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities.

• ·        define the biology of prostate cancer progression to lethal prostate cancer to reduce death

applications must be directly related to high-risk, very high-risk, and metastatic prostate cancer.  refer to the national comprehensive cancer network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

funding opportunities-fy22 pcrp, congressionally directed medical research programs (cdmrp), us dod (army.mil)

translational science award – letter of intent due august 4, 2022

independent investigators at all levels

• ·      supports advanced translational research that will foster transformation of promising ideas in prostate cancer into clinical applications, ultimately providing a solution to one or more of the fy22 pcrp overarching challenges.
• ·      translational research may be defined as an integration of basic science and clinical observations, including a reciprocal flow of ideas and information from bench to beside and/or bedside to bench.
• ·      supports a broad range of translational studies such as:

o   advanced translation of results from animal studies to applications with human samples/cohorts 

o   late-stage preclinical work leading to/preparing for a clinical trial, e.g., investigational new drug application submission

o   correlative studies that are associated with an open/ongoing or completed clinical trial, e.g., projects that utilize biospecimens from clinical trial to improve clinical management of prostate cancer and/or define new areas of research

o   projects that develop endpoints for clinical trials

• ·      preliminary data to support the scientific rationale and feasibility of the research approaches are required.  the inclusion of additional preliminary data to support the clinical relevance of the idea is strongly encouraged.
• ·      clinical trials are not allowed.
• ·      partnering pi option:  allows two pis, termed initiating and partnering pis, to collaborate on a single application.  collaborations between basic science and clinical researchers are highly encouraged.
• ·      must address at least one of the fy22 pcrp overarching challenges
• ·     the maximum allowable funding for the entire period of performance is $900,000 for direct costs.
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·     the maximum period of performance is 3 years.

health disparity research award – letter of intent due august 4, 2022

established investigators:  independent investigators at all levels

new investigators:  investigators that meet the following criteria at the application submission deadline date:

• ·      have the freedom to pursue individual aims without formal mentorship
• ·      have not previously received a pcrp health disparity research award and/or idea development award

have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of a terminal degree (excluding residency or family medical leave)

• ·      supports research ideas that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality.
• ·      proposed projects must address one of the following health disparity focus areas:  (1) biological contributors, (2) environmental factors, (3) social and cultural factors, or (4) access to healthcare.
• ·      proposed projects may include basic, translational, or clinical research, including clinical trials.
• ·      primary emphasis will be placed on the potential impact of the proposed work.
• ·      preliminary data are encouraged, but not required.

must address at least one of the fy22 pcrp overarching challenges.

• ·     the maximum allowable funding for the entire period of performance is $900,000 for direct costs.
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

the maximum period of performance is 3 years.

data science award – letter of intent due august 4, 2022

independent investigators at all levels

supports research where quantitative and analytical approaches, processes, and/or systems are developed and/or used to obtain knowledge and insight from large and/or complex sets of prostate cancer data.

• ·      applications may propose development of a new data-science-driven tool or apply an existing tool or method to gather and analyze information from large data sets with the intent of advancing prostate cancer research and patient care relative to the fy22 pcrp overarching challenges.
• ·      research efforts must be built upon the logic, concepts, and methods of one or more of the following research areas as they pertain to prostate cancer:

o   computational biology

o   bioinformatics

o   artificial intelligence and machine learning

o   epidemiology

o   analysis of -omics data

o   medical imaging

o   digital pathology

o   analysis of clinically annotated datasets

• ·      clinical research is allowed, but must be retrospective; prospective recruitment of human subjects and/or clinical trials is not allowed.
• ·      presentation of preliminary data is strongly encouraged, but not required.
• ·      partnering pi option:  allows two pis, termed initiating and partnering pis, to collaborate on a single application.  collaborations between data scientists and clinicians are highly encouraged.  at least one of the submitting or partnering pis must have expertise in prostate cancer basic and/or clinical research.
• ·      must address at least one of the fy22 pcrp overarching challenges.
• ·     the maximum allowable funding for the entire period of performance is $1,000,000 for direct costs.
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 3 years.

for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca.

the fy22 defense appropriations act is anticipated to provide funding for the pcrp to support innovative, high-impact prostate cancer research.  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 pcrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

the mission of the fy22 pcrp is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of service members, veterans, and all the men and their families who are experiencing the impact of the disease.  within this context, the pcrp is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following fy22 pcrp overarching challenges:

• ·        improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer

applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness.  studies should consider both short- and long-term quality of life outcomes.  areas of particular interest include:

o   the mental and emotional health of patients and their families/caregivers

o   impact of quality of life considerations on decision-making after diagnosis and/or treatment

o   identification of vulnerable groups of men and their families at great risk of quality of life detriments

o   translation of factors or interventions that improve quality of life outcomes and overall health and wellness

• ·        develop treatments that improve outcomes for men with lethal prostate cancer

applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence.  refer to the national comprehensive cancer network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

• ·        advance health equity and reduce disparities in prostate cancer

applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer. 

inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors.

health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients. 

high-risk populations include, but are not limited to, people of african descent (including caribbean), genetically predisposed populations, service members, and veterans.

underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities.

• ·        define the biology of prostate cancer progression to lethal prostate cancer to reduce death

applications must be directly related to high-risk, very high-risk, and metastatic prostate cancer.  refer to the national comprehensive cancer network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

early investigator research award – letter of intent due by july 7, 2022

by march 31, 2023, postdoctoral principal investigators (pis):

• ·      must possess a doctoral degree (or equivalent)
• ·      have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training)
• ·      supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.
• ·      pis must have a designated mentor who is an experienced prostate cancer researcher.
• ·      must include a researcher development plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the pi’s career development.
• ·      must address at least one of the fy22 pcrp overarching challenges.
  • ·     the maximum allowable funding for the entire period of performance is $300,000 for direct costs.
  • ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • ·     the maximum period of performance is 2 years.

physician research award – letter of intent due by july 7, 2022

at the time of application submission, the pi must be either:

• ·    in the last year of an accredited medical residency or medical fellowship program

or

within 5 years of having initiated a faculty appointment (including instructor positions)

• ·     supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.
• ·     pis must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.
• ·     pis must have a designated mentor with an established research program in prostate cancer.
• ·     applications are strongly encouraged to demonstrate protection of at least 40% of the pi’s time for prostate cancer research (not required to be exclusive to this award). 
• ·     must include a researcher development plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the pi’s career development.
• ·     must address at least one of the fy22 pcrp overarching challenges.
• ·     the maximum allowable funding for the entire period of performance is $750,000 for direct costs.
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·     the maximum period of performance is 4 years.

idea development award – letter of intent due by july 7, 2022

established investigators:  independent investigators at all levels

new investigators:  investigators that meet the following criteria at the application submission deadline date:

• ·      have the freedom to pursue individual aims without formal mentorship
• ·      have not previously received a pcrp health disparity research award and/or idea development award
• ·      have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of a terminal degree (excluding residency or family medical leave)
  • ·      supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the fy22 pcrp overarching challenges.
  • ·      emphasis is equally placed on innovation and impact.
  • ·      preliminary data are encouraged, but not required.
  • ·      clinical trials are not allowed.
  • ·      multidisciplinary projects are encouraged, and multi-institutional projects are allowed.
  • ·      must address at least one of the fy22 pcrp overarching challenges.
  • ·     the maximum allowable funding for the entire period of performance is $900,000 for direct costs.
  • ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • ·     the maximum period of performance is 3 years.
     
     
    for more information, please contact jill sherman, international research facilitator at  intl.research@lakeheadu.ca.

the fy22 defense appropriations act is anticipated to provide funding for the pcrp to support innovative, high-impact prostate cancer research.  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 pcrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website.

the mission of the fy22 pcrp is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of service members, veterans, and all the men and their families who are experiencing the impact of the disease.  within this context, the pcrp is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following fy22 pcrp overarching challenges:

• ·        improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer

applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness.  studies should consider both short- and long-term quality of life outcomes.  areas of particular interest include:

o   the mental and emotional health of patients and their families/caregivers

o   impact of quality of life considerations on decision-making after diagnosis and/or treatment

o   identification of vulnerable groups of men and their families at great risk of quality of life detriments

o   translation of factors or interventions that improve quality of life outcomes and overall health and wellness

• ·        develop treatments that improve outcomes for men with lethal prostate cancer

applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence.  refer to the national comprehensive cancer network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

• ·        advance health equity and reduce disparities in prostate cancer

applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer. 

inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors.

health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients. 

high-risk populations include, but are not limited to, people of african descent (including caribbean), genetically predisposed populations, service members, and veterans.

underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities.

• ·        define the biology of prostate cancer progression to lethal prostate cancer to reduce death

applications must be directly related to high-risk, very high-risk, and metastatic prostate cancer.  refer to the national comprehensive cancer network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/pdf/prostate-advanced-patient.pdf).

funding opportunities-fy22 pcrp, congressionally directed medical research programs (cdmrp), us dod (army.mil)

exploration – hypothesis development award new for fy22 –letter of intent dye june 2, 2022

investigators at or above the level of postdoctoral fellow (or equivalent)

• ·     supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more fy22 pcrp overarching challenges.
• ·     provides investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation.
• ·     presentation of preliminary data is strongly discouraged.
• ·     reviewers will be blinded to the identity of the principal investigator (pi), collaborators, and their organization(s).
• ·     clinical research and clinical trials are not allowed.
• ·     must address at least one of the fy22 pcrp overarching challenges.
• ·     the maximum allowable funding for the entire period of performance is $100,000 for direct costs.
• ·     indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 2 years.

for more information, please contact jill sherman, international research facilitator at intl.research@lakeheadu.ca.

background and description of opportunity

the canadian glycomics network (glyconet) is a network of centres of excellence that focuses on the role of glycans (carbohydrates) in health. areas of focus for glyconet in cycle ii (2020–2024) are infectious diseases, chronic diseases (including diabetes & obesity), neurodegenerative diseases, and cancer. additional information about network research can be found at www.glyconet.ca.

a key goal of glyconet is to support research projects that are multi-disciplinary, as defined by the nce program. accordingly, this request for proposals seeks to fund projects that involve two or more research groups in different disciplines.

requirements project applications must:

• primarily address the glyconet research themes and be targeted to the role/use of glycans in reducing the economic burden and/or treatment of infectious diseases, chronic diseases, neurodegenerative diseases, and/or cancer. research in other areas of glycomics will be considered, especially those in one health.

• must have multi-disciplinary teams involving researchers as described above.

• provide a plan of how equity, diversity and inclusion will be implemented within the project team and its activities.

• lead to tangible deliverables by the end of the project, leading to translational research as the next step.

• present a knowledge mobilization plan to communicate results to partners and stakeholders.

• demonstrate a 1:1 financial match with partner funding; at least 50% of the matching funds should be cash. partner funding must be nce eligible; in particular, other canadian federal funding (e.g., cihr, nserc, sshrc, cfi) is ineligible for matching.

• projects with a higher level of matching funds (e.g. 2:1, partners:glyconet) will be viewed more favorably.

• provide information on the number and type (i.e. undergraduate, graduate student, pdf, etc.) of expected highly qualified personnel trained each year of the project.

• list the desired type of professional development training that glyconet could provide to hqp, for example, lab rotations, communication and writing skills improvement, etc.

the objectives of the program are to address systemic racism and discrimination and advance health equity for racialized and marginalized populations in canada's health systems, resulting in:

• individuals living in canada having access to appropriate, effective, and culturally sensitive health services; and,
• improved health of racialized and marginalized populations.

idrc and the united kingdom’s foreign, commonwealth and development office are pleased to announce a call for concept notes under the climate adaptation and resilience (clare) initiative.  

this call for concept notes seeks to identify transdisciplinary teams motivated to conduct action-oriented research related to one or more of clare’s three research themes:  

• understanding climate risk: research to improve our understanding of the risks associated with climate and natural hazards, by addressing gaps in the underpinning science.   
• risk-informed early action: research to improve risk-informed anticipatory action to reduce humanitarian and extreme impacts of weather, climate variability and the compounding and cascading interaction of natural hazards.  
• developing in a changing climate: research to inform development in a changing climate; action that builds resilience in the present climate and adapts to future climate.  

overview

canada’s international development research centre (idrc) and the canadian institutes of health research’s institute of population and public health (cihr-ipph) are pleased to announce a new funding opportunity to identify and implement effective knowledge mobilization strategies to integrate the canadian coalition for global health research’s (ccghr) principles for global health research (known hereafter as the principles) across the global health research ecosystem.

the principles were developed by the ccghr (now, the canadian association for global health) through a consultative process that involved over 300 people within and outside canada. developed for all those involved in global health research (ghr) — including people designing, conducting, using, teaching, learning about, assessing, funding or collaborating on ghr — the principles identify equity as a central pillar. the six principles are: authentic partnering, inclusion, shared benefits, commitment to the future, responsiveness to the causes of inequities and humility.

since their publication in 2015, the principles are increasingly seen as an exemplar in global health and health equity more broadly. however, awareness of these principles and their uptake can be further strengthened. the goal of this funding opportunity is to support the fulsome integration of the principles into action across the canadian ghr ecosystem. by supporting action on the principles, we can ensure global health is practised in an equitable way and is actively anti-colonial in its orientation.

background

for many people, the raison d’être of global health is the achievement of health equity for all people worldwide. reaffirming this view is the united nations’ sustainable development goal (sdg) #3 which seeks to “ensure healthy lives and promote well-being for all at all ages.” yet, after decades of programming and billions of dollars invested in global health, alarming health inequities persist across and within countries. the current covid-19 pandemic has further exacerbated these health inequities, underscoring the need for the field of global health to do more and to do better.

global health is an area for study, research and practice that places a priority on improving health and achieving equity in health for all people worldwide. ghr — research focused on achieving health equity globally — can make important contributions to advancing the sustainable development goals. ghr is paradoxically also culpable in perpetuating the same health inequities that it generally seeks to understand and address. for example, the rising calls for the decolonization of global health have called out practices such as ‘parasitic research’ and ‘foreign gaze’ as symptoms of the deeply entrenched power imbalances between global health researchers and populations in high-income countries (hics) and those in low- and middle-income countries (lmics).

responding to the need to ensure ghr is conducted in an ethical way, the ccghr (now, the canadian association for global health) developed the principles for global health research (the principles) through a consultative process that involved over 300 people. developed for all those involved in ghr — including people designing, conducting, using, teaching, learning about, assessing, funding or collaborating on ghr — the principles identify equity as a central pillar. the six principles are: authentic partnering, inclusion, shared benefits, commitment to the future, responsiveness to the causes of inequities and humility.

since their publication in 2015, the principles are increasingly being used by the ghr community, including by universities, non-academic research organizations, governmental bodies and non-governmental organizations, to inform training, curriculum development, research design and research funding. they are seen as an exemplar in global health and health equity more broadly. the time is ripe to mobilize their integration across the ghr ecosystem.

aim and objectives

the overall goal of this call is to support the identification and implementation of effective knowledge mobilization strategies for integrating the principles into action across the canadian ghr ecosystem. by supporting action on the principles, we hope to ensure global health is practised in an equitable way and is actively anti-colonial in its orientation.

specifically, the call seeks to support research and knowledge mobilization activities that will rigorously:

1. take stock of awareness and application of the principles within the canadian ghr ecosystem (including researchers, universities and academic settings, research and policy partners in lmics, ngos and research funders);
2. identify and implement the best strategies and opportunities for encouraging the uptake and institutionalization of the principles across the canadian ghr ecosystem; and
3. create open-access tools and resources and provide guidance and support to facilitate and scale-up the use and institutionalization of the principles in canada and around the world.

for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca.

the r&d partnership fund - electric vehicle (ev) – stream 2 program supports projects related to the development and demonstration of technologies in electric vehicles (ev) and battery manufacturing technologies in the following priority areas:

• mass light vehicles, such as cars, trucks and vans
• heavy duty vehicles, including commercial vehicles, trucks, buses, recreational vehicles (rvs), and others used for goods movement
• charging infrastructure
• intelligent transportation systems (its)
• transit-supportive systems and vehicles

examples of ev and battery-focused technologies, and other ev related technologies:

• light weighting
• electrified powertrains, electric motors, transmission systems, battery management systems
• ev batteries, battery materials and chemistry, component manufacturing processes
• charging systems and ev fleet management technologies
• hydrogen and alternative fuel cell evs
• electric micro-mobility

the r&d partnership fund - c/av and smart mobility – stream 2 program supports projects related to the development, testing, validation, and demonstration of connected and autonomous vehicle (c/av) and smart mobility technologies in the following priority areas:

• mass light vehicles, such as cars, trucks, and vans
• heavy duty vehicles, including commercial vehicles, trucks, buses, recreational vehicles (rvs), and others used for goods movement
• transportation infrastructure
• intelligent transportation systems (its)
• transit-supportive systems and vehicles